![DSpace logo](/jspui/image/logo.gif)
Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13622
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jindal, Anil B. | - |
dc.date.accessioned | 2024-01-03T05:07:04Z | - |
dc.date.available | 2024-01-03T05:07:04Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0168365923005436 | - |
dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13622 | - |
dc.description.abstract | The Global Technical Strategy for Malaria 2016–2030 aims to achieve a 90% reduction in malaria cases, and strategic planning and execution are crucial for accomplishing this target. This review aims to understand the complex interaction between erythrocytic receptors and parasites and to use this knowledge to actively target the erythrocytic stage of malaria. The review provides insight into the malaria life cycle, which involves various receptors such as glycophorin A, B, C, and D (GPA/B/C/D), complement receptor 1, basigin, semaphorin 7a, Band 3/ GPA, Kx, and heparan sulfate proteoglycan for parasite cellular binding and ingress in the erythrocytic and exo-erythrocytic stages. Synthetic peptides mimicking P. falciparum receptor binding ligands, human serum albumin, chondroitin sulfate, synthetic polymers, and lipids have been utilized as ligands and decorated onto nanocarriers for specific targeting to parasite-infected erythrocytes. The need of the hour for treatment and prophylaxis against malaria is a broadened horizon that includes multiple targeting strategies against the entry, proliferation, and transmission stages of the parasite. Platform technologies with established pre-clinical safety and efficacy should be translated into clinical evaluation and formulation scale-up. Future development should be directed towards nanovaccines as proactive tools against malaria infection. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.subject | Pharmacy | en_US |
dc.subject | pRBC | en_US |
dc.subject | Immunoliposomes | en_US |
dc.subject | GLUT-1 | en_US |
dc.subject | Glycosaminoglycan | en_US |
dc.subject | Human serum albumin | en_US |
dc.title | Nanocarrier based active targeting strategies against erythrocytic stage of malaria | en_US |
dc.type | Article | en_US |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.